ARS Pharmaceuticals, Inc. SPRY Increase (decrease) in contract liabilities and current deferred income
Increase (decrease) in contract liabilities and current deferred income at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income?
- ARS Pharmaceuticals, Inc. (SPRY) reported increase (decrease) in contract liabilities and current deferred income of -$61K in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income changed year-over-year?
- ARS Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income increased by 71.0% year-over-year, from -$210K to -$61K.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income?
- Over 3 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income has grown at a -48.1% compound annual growth rate (CAGR), from -$2.51M to -$350K.